Besides, all enrolled patients in our study developed metastatic disease, which suggested that these patients had aggressive prognostic factors, and not all patients received anti-HER2 adjuvant treatment due to expense, all of which might cause a shorter DFS in our study than previous results [31]. Here, ERBB2 is linked to metastatic neoplasm.